Patients
Already the leader in epilepsy, UCB is committed to providing novel solutions for people with severe conditions such as Parkinson's disease, rheumatoid arthritis, restless legs syndrome,...
Top of this page
Skip navigation, go straight to the content
At UCB our sense of purpose is to help people suffering from severe central nervous system or immunological disorders lead normal, everyday lives. Our ambition is to offer them innovative new medicines and ground-breaking solutions that go beyond the drug. We are committed to enabling cutting-edge scientific research that is driven by the patients' needs.
UCB, headquartered in Brussels, Belgium, is a global biopharma company with a team of over 8500 talented employees, a strong market presence in more than 40 countries, € 3.2 billion in revenue (2010) and numerous strategic partnerships across the industry.
Products
UCB medicines are making a real difference to the lives of people all over the world. Some of our products are among the leaders in their field.
Job seekers
Join us and make a world of difference as we built the next generation biopharma, supported by a dynamic team in over 40 countries.
R&D
UCB’s goal is to command a leading position in discovering and developing new therapies to treat patients suffering from severe diseases.
